ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Clinical Characteristics and Development of a Risk-Identification Model for Incidentally Detected Cancer in Patients with Diabetes: A Case-Control Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In hospitalised adults with diabetes, asymptomatic cancers may be overlooked during admission, delaying diagnosis and potentially contributing to poorer prognosis by missing opportunities for earlier treatment. Although cross-sectional imaging can detect lesions, it is not systematically performed in asymptomatic patients. A risk signal from routine measurements could prompt targeted imaging and enable diagnosis. Methods: We conducted a single-centre retrospective case-control study at Xinhua Hospital. Cases were adults with diabetes with first, pathology-confirmed cancer (any site) detected incidentally during index admission without cancer-related symptoms. Controls were inpatients matched by age and diabetes duration. We developed two models. Model A predictors were age, sex, body mass index, HbA1c, mean glucose, mean amplitude of glycaemic excursions (MAGE) from the first 72 h of capillary glucose, 2-hour C-peptide, apolipoprotein A-I (ApoA-I), albumin, and sodium-glucose cotransporter 2 (SGLT2) inhibitor use. Model B added carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125), and cytokeratin 19 fragment (CYFRA21-1); albumin was not retained. Performance was assessed by area under the receiver operating characteristic curve (AUC), calibration, Brier score, decision curve analysis (DCA), and net reclassification improvement (NRI). Results: Of 281 patients, 140 were cases and 141 were controls. Model A used 219 participants and Model B 156 participants. Higher 2-hour C-peptide and ApoA-I were associated with lower odds of cancer, whereas higher CYFRA21-1 was associated with higher odds. Model B outperformed Model A (AUC 0.740 to 0.852; Brier 0.199 to 0.147). Conclusion: Using inpatient measurements, we developed a risk-identification model for incidentally detected, asymptomatic cancer among hospitalised adults with diabetes, which may help prioritise in-hospital diagnostic work-up. Adding tumour markers, particularly CYFRA21-1, improved discrimination. Prospective multicentre validation and assessment of clinical and economic impact are warranted before implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.